SCHEMBL4229667

SCHEMBL4229667

CN(C)[C@H]1CCN(c2ccc(NC(=O)Nc3ccc(-c4cncc5c4cnn5C)cc3)cc2C(F)(F)F)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.48
CSF1R P07333 6/20 0.43
FLT4 P35916 4/20 0.43
LYN P07948 3/20 0.43
KIT P10721 3/20 0.43
FLT1 P17948 3/20 0.43
BLK P51451 3/20 0.43
DYRK3 O43781 2/20 0.43
ROCK2 O75116 2/20 0.43
MAP4K4 O95819 2/20 0.43
RET P07949 2/20 0.43
MET P08581 2/20 0.43
FGFR1 P11362 2/20 0.43
RPS6KB1 P23443 2/20 0.43
EPHA2 P29317 2/20 0.43
MATK P42679 2/20 0.43
FRK P42685 2/20 0.43
CSNK1A1 P48729 2/20 0.43
CSNK1D P48730 2/20 0.43
CLK2 P49760 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4220062 1.00 KDR (0.48) KDRCSF1RFLT4LYNKIT
SCHEMBL4220058 1.00 KDR (0.48) KDRCSF1RFLT4LYNKIT
SCHEMBL4224044 0.95 KDR (0.49) KDRCSF1RFLT4LYNKIT
SCHEMBL3847504 0.90 KDR (0.51) KDRCSF1RFLT4LYNKIT
SCHEMBL13910072 0.89 KDR (0.46) KDRCSF1RFLT4LYNKIT
SCHEMBL3848258 0.89 KDR (0.46) KDRCSF1RFLT4LYNKIT
SCHEMBL4222658 0.89 KDR (0.51) KDRCSF1RFLT4LYNKIT
SCHEMBL4221218 0.87 RET (0.49) KDRCSF1RFLT4LYNKIT
SCHEMBL13910075 0.87 RET (0.49) KDRCSF1RFLT4LYNKIT
SCHEMBL3844663 0.87 RET (0.49) KDRCSF1RFLT4LYNKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125808-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME Bayer Schering Pharma Aktiengesellschaft (DE) 2009-12-02 EP claimed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US claimed
WO-2008071456-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO claimed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. KDR, FLT4, TIE1 KDR 1/4885CSF1R 1363/4885FLT4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.